Takeda

News

Scotland backs Roche’s Rozlytrek for ROS1 lung cancer

The Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of lung cancer, almost seven months after NICE backed the drug in England.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J’s Darzalex Faspro is first US therapy for rare blood dis...

Johnson & Johnson’s Darzalex Faspro has become the first product approved by the FDA to treat light chain (AL) amyloidosis, a rare and often fatal blood cell disorder.

News

Pandemic has little impact on pharma's reputation, says repo...

The pandemic has had very little positive impact on the public’s perceptions of pharma although the industry has fared much better than politicians, according to a report.

News

Takeda to partner on patient-centric data with Seqster

Takeda has partnered with patient data firm Seqster in a drive to improve care through better access and understanding of patient-level data.

News

Takeda’s bleeding disorder drug Veyvondi backed for NHS use

NHS England has recommended that patients with von Willebrand disease (VWD) be treated with Takeda’s Veyvondi, making it the first and only medicine backed for what is the most common inher

News

A healthy discussion on funding tomorrow’s treatments

Despite biosims, ulcerative colitis drugs still cost too muc...

None of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough to be cost-effective, says the Institute for Clinical and Economic Review

Scotland backs Roche’s Rozlytrek for ROS1 lung cancer

J&J’s Darzalex Faspro is first US therapy for rare blood dis...

Pandemic has little impact on pharma's reputation, says repo...

Takeda to partner on patient-centric data with Seqster

Takeda’s bleeding disorder drug Veyvondi backed for NHS use

Despite biosims, ulcerative colitis drugs still cost too muc...

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Takeda

Editor's Picks